The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease
Open accessAbstract
Aims In December 2019, the Coronavirus disease-2019 (COVID-19) virus has emerged in Wuhan, China. In this research, the first resolved COVID-19 crystal structure (main protease) was targeted in a virtual screening study by of FDA approved drugs dataset. In addition, a knowledge gap in relations of COVID-19 with the previously known fatal Coronaviruses (CoVs) epidemics, SARS and MERS CoVs, was covered by investigation of sequence statistics and phylogenetics. Materials and methods Molecular modeling, virtual screening, docking, sequence comparison statistics and phylogenetics of the COVID-19 main protease were investigated. Key findings COVID-19 Mpro formed a phylogenetic group with SARS CoV that was distant from MERS CoV. The identity% was 96.061 and 51.61 for COVID-19/SARS and COVID-19/MERS CoV sequence comparisons, respectively. The top 20 drugs in the virtual screening studies comprised a broad-spectrum antiviral (ribavirin), anti-hepatitis B virus (telbivudine), two vitamins (vitamin B12 and nicotinamide) and other miscellaneous systemically acting drugs. Of special interest, ribavirin had been used in treating cases of SARS CoV. Significance The present study provided a comprehensive targeting of the first resolved COVID+19 structure of Mpro and found a suitable save drugs for repurposing against the viral Mpro. Ribavirin, telbivudine, vitamin B12 and nicotinamide can be combined and used for COVID treatment. This initiative relocates already marketed and approved safe drugs for potential use in COVID-treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Friesner, R. A., Banks, J. L., Murphy, R. B., Halgren, T. A., Klicic, J. J., Mainz, D. T., Repasky, M. P., Knoll, E. H., Shelley, M., Perry, J. K., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm0306430 · Cited by 10,057 · cited 1×
“In order to get accurate results, the standard precision (SP docking) was selected [27, 28] .”
Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi Arabia
Zaki, A. M., van Boheemen, S., Bestebroer, T. M., Osterhaus, A. D. M. E., & Fouchier, R. A. M. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1211721 · Cited by 5,735
Halgren, T. A., Murphy, R. B., Friesner, R. A., Beard, H. S., Frye, L. L., Pollard, W. T., & Banks, J. L. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm030644s · Cited by 5,177
Wan, Y., Shang, J., Graham, R., Baric, R. S., & Li, F. (2020) · Journal of Virology · doi:10.1128/jvi.00127-20 · Cited by 4,341
Coronavirus as a possible cause of severe acute respiratory syndrome
Peiris, J., Lai, S., Poon, L., Guan, Y., Yam, L., Lim, W., Nicholls, J., Yee, W., Yan, W., Cheung, M., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13077-2 · Cited by 2,915
Xu, X., Chen, P., Wang, J., Feng, J., Zhou, H., Li, X., Zhong, W., & Hao, P. (2020) · Science China Life Sciences · doi:10.1007/s11427-020-1637-5 · Cited by 2,205
Coronaviruses — drug discovery and therapeutic options
Zumla, A., Chan, J. F. W., Azhar, E. I., Hui, D. S. C., & Yuen, K.-Y. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.37 · Cited by 1,707
The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen
Crotty, S., Maag, D., Arnold, J. J., Zhong, W., Lau, J. Y. N., Hong, Z., Andino, R., & Cameron, C. E. (2000) · Nature Medicine · doi:10.1038/82191 · Cited by 820
From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design
Hilgenfeld, R. (2014) · The FEBS Journal · doi:10.1111/febs.12936 · Cited by 660
Wen, C.-C., Kuo, Y.-H., Jan, J.-T., Liang, P.-H., Wang, S.-Y., Liu, H.-G., Lee, C.-K., Chang, S.-T., Kuo, C.-J., Lee, S.-S., et al. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070295s · Cited by 576
Three Emerging Coronaviruses in Two Decades
Guarner, J. (2020) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqaa029 · Cited by 503
Recent discovery and development of inhibitors targeting coronaviruses
Pillaiyar, T., Meenakshisundaram, S., & Manickam, M. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.01.015 · Cited by 361
Li, W., Wong, S.-K., Li, F., Kuhn, J. H., Huang, I.-C., Choe, H., & Farzan, M. (2006) · Journal of Virology · doi:10.1128/jvi.80.9.4211-4219.2006 · Cited by 276
Zhou, Z., Khaliq, M., Suk, J.-E., Patkar, C. G., Li, L., Kuhn, R. J., & Post, C. B. (2008) · ACS Chemical Biology · doi:10.1021/cb800176t · Cited by 136
Ribavirin in the treatment of SARS: A new trick for an old drug?
Koren, G., King, S., Knowles, S. R., & Phillips, E. W. (2003) · Europe PMC (PubMed Central) · Cited by 124
In silico virtual screening approaches for anti-viral drug discovery
Murgueitio, M. S., Bermúdez, M., Mortier, J., & Wolber, G. (2012) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2012.07.009 · Cited by 118
Virtual Screening for SARS-CoV Protease Based on KZ7088 Pharmacophore Points
Sirois, S., Wei, D., Du, Q.-S., & Chou, K. (2004) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci034270n · Cited by 118
Raj, U., & Varadwaj, P. K. (2015) · Interdisciplinary Sciences Computational Life Sciences · doi:10.1007/s12539-015-0109-8 · Cited by 96
Sheikh, A., Al-Taher, A. Y., Al-Nazawi, M. H., Al-Mubarak, A. I. A., & Kandeel, M. K. (2020) · Journal of Virological Methods · doi:10.1016/j.jviromet.2019.113806 · Cited by 77
Self-citationMolecular Characteristics, Functions, and Related Pathogenicity of MERS-CoV Proteins
Li, Y.-H., Hu, C.-Y., Wu, N.-P., Yao, H., & Li, L.-J. (2019) · Engineering · doi:10.1016/j.eng.2018.11.035 · Cited by 61
Introduction of SARS in France, March–April, 2003
Desenclos, J., van der Werf, S., Bonmarin, I., Lévy-Bruhl, D., Yazdanpanah, Y., Hoen, B., Emmanuelli, J., Lesens, O., Dupon, M., Natali, F., et al. (2004) · Emerging infectious diseases · doi:10.3201/eid1002.030351 · Cited by 53
SARS‐CoV protease inhibitors design using virtual screening method from natural products libraries
Liu, B., & Zhou, J. (2005) · Journal of Computational Chemistry · doi:10.1002/jcc.20186 · Cited by 39
ElHefnawi, M., ElGamacy, M., & Fares, M. (2012) · BMC Bioinformatics · doi:10.1186/1471-2105-13-s17-s5 · Cited by 34
Cited by
Structural biology of SARS-CoV-2: open the door for novel therapies
Yan, W., Zheng, Y., Zeng, X., He, B., & Cheng, W. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00884-5 · Cited by 291
Moustaqil, M., Ollivier, E., Chiu, H.-P., Van Tol, S., Rudolffi-Soto, P., Stevens, C., Bhumkar, A., Hunter, D. J. B., Freiberg, A. N., Jacques, D., et al. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1870414 · Cited by 283
Could Vitamins Help in the Fight Against COVID-19?
Jovic, T. H., Ali, S. R., Ibrahim, N., Jessop, Z. M., Tarassoli, S. P., Dobbs, T. D., Holford, P., Thornton, C. A., & Whitaker, I. S. (2020) · Nutrients · doi:10.3390/nu12092550 · Cited by 234
Metadata
- Authors
- Kandeel, M., & Al-Nazawi, M.
- Venue
- Life Sciences
- Publisher
- Elsevier BV
- Published
- 2020-06
- Volume
- 251
- Pages
- 117627
- ISSN
- 0024-3205 (ISSN-L)
- OpenAlex
- W3014852814
- Cited by
- 412
- References
- 23
- FWCI
- 44.43
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.